300363 Porton Pharma Solutions
- 20.46
- -0.74-3.49%
Porton Pharma Solutions News
Boteng Co., Ltd.: 2021 Annual Equity Distribution Implementation Notice
Boteng Co., Ltd.: 2021 Profit Distribution Plan
Boteng Co., Ltd.: Announcement on the acquisition of 100% of Kaihui Pharmaceutical (Shanghai) Co., Ltd.
Boteng Co., Ltd.: Announcement on the progress of acquiring 70% of the shares of Hubei Yuyang Pharmaceutical Co., Ltd.
Boteng Co., Ltd.: Announcement on the acquisition of 70% of the shares of Hubei Yuyang Pharmaceutical Co., Ltd.
Boteng Co., Ltd.: Announcement on transfer of minority shares in Zhejiang Huishi Pharmaceutical Co., Ltd.
Boteng Co., Ltd.: Announcement on transfer of 60% of the shares of Zhejiang Boteng, a holding subsidiary
Boteng Co., Ltd.: Announcement on the termination of planning asset purchases
Boten Co., Ltd.: Announcement on the progress of asset acquisition matters
Trading of Boten shares has been suspended since the opening of the market on February 5, 2018
Trading of Boteng Co., Ltd. has been suspended since the opening of the market on July 18, 2017
Boteng Co., Ltd.: Prompt announcement on participation in equity bidding for overseas projects
Boten Co., Ltd.: Announcement on approval of registration of medium-term notes
Boteng Co., Ltd.: Announcement on the Company's Transfer of Part of Land Use Rights and Related Transactions
Boteng Co., Ltd.: Announcement of Resolutions of the 36th Interim Meeting of the 2nd Board of Directors
Boten Co., Ltd.: Announcement on the proposed issuance of medium-term notes
Boteng Co., Ltd.: Announcement of Resolutions of the 34th Interim Meeting of the 2nd Board of Directors
Boteng Co., Ltd.: Report on Issuance of Shares and Payment of Cash to Purchase Assets and Raise Supporting Funds (Revised Draft)
Boteng Co., Ltd.: Notice on Revised Instructions for Issuing Shares and Paying Cash to Purchase Assets and Raise Supporting Funds
Boteng Co., Ltd.: Announcement on the company's issuance of shares and payment of cash to purchase assets and raise supporting funds received official approval from the China Securities Regulatory Commission
Analysis
Price Target
No Data
No Data